Results of Surgical Coronary Revascularization Alone Versus Combined Surgical Revascularization and Mitral Valve Repair in Patients With Moderate Ischemic Mitral Regurgitation
Background: This is a prospective randomized-controlled study aiming to determine whether the optimal surgical management of moderate ischemic mitral regurgitation is to revascularize the heart through performing coronary artery bypass grafting alone or together with repairing the mitral valve.
Methods: Between April 2014 and November 2014,
40 patients with ischemic heart disease associated with moderate ischemic mitral regurgitation at our University hospitals were divided into 2 matched groups. Group 1 received both coronary artery bypass grafting surgery together with mitral valve repair, while Group 2 underwent coronary artery bypass grafting surgery alone.
Results: No statistically significant difference was found between both study groups, in terms of operative data, except for cardiopulmonary bypass time and aortic cross-clamp time, which were significantly longer in Group 1 (P < .001). Only one case died in the study in Group 1 on the third postoperative day, due to severe low cardiac output syndrome. During the follow up, NYHA class improved in Group 1 from 2.6 to 1.35 (P < .004), but in Group 2 NYHA class improved from 2.55 to 1.72 (P = .07). The degree of MR improved in
19 patients (95%) in Group 1 compared with 15 (75%) patients in Group 2 (P < .0001).
Conclusion: Our study showed meaningful advantages of adding mitral-valve repair to CABG in patients with ischemic heart disease and moderate ischemic mitral regurgitation, regarding the degree of MR and functional NYHA class. On the other hand, there was no statistically significant difference between both groups in postoperative coarse and in-hospital mortality.
Aklog L, Filsoufi F, Flores KQ, et al. 2001. Does coronary artery bypass grafting alone correct moderate ischaemic mitral regurgitation? Circulation 104:68–75.
Bax JJ, Braun J, Somer ST, et al. 2004. Restrictive annuloplasty and coronary revascularization in ischemic mitral regurgitation results in reverse left ventricular remodeling. Circulation 110:103.
Calafiore AM, Di Mauro M, Gallina S, Di Giammarco G, Iacò AL, Teodori G, Tavarozzi I. 2004. Mitral valve surgery for chronic ischemic mitral regurgitation. Ann Thorac Surg 77:1989-1997.
Campwala ZC, Bansal RC, Wang N, Razzouk A, Pai RG, et al. 2006. Mitral regurgitation progression following isolated coronary artery bypass surgery: frequency, risk factors, and potential prevention strategies. Eur J Cardiothorac Surg 29:348-354.
Di Mauro M, Di Giammarco G, Vitolla G, Contini M, Iaco` AL, Bivona A, et al. 2006. Impact of no-to-moderate mitral regurgitation on late results after isolated coronary artery bypass grafting in patients with ischemic cardiomyopathy. Ann Thoracic Surg. 81:2128-34.
Duarte IG, Shen Y, MacDonald MJ, Jones EL, Craver JM, Guyton RA. 1999. Treatment of moderate mitral regurgitation and coronary disease by coronary bypass alone: late results. Ann Thoracic Surg. 68:426-30.
El Bardissi AW, Aranki SF, Sheng S, O'Brien SM, Greenberg CC, Gammie JS. 2012. Trends in isolated coronary artery bypass grafting: an analysis of the Society of Thoracic Surgeons adult cardiac surgery database. J Thorac Cardiovasc Surg 143:273-281.
Fattouch K, Guccione F, Sampognaro R, Panzarella G, Corrado E, Navarra E, Calvaruso D, Ruvolo G. 2009. Impact of Moderate Ischemic Mitral Regurgitation After Isolated Coronary Artery Bypass Grafting, J. of Thoracic and Cardiovascular Surgery 138:278-285.
Fattouch K, Guccione F, Sampognaro R, Panzarella G, Corrado E, Navarra E, Calvaruso D, Ruvolo G. 2009. POINT: Efficacy of adding mitral valve restrictive annuloplasty to coronary artery bypass grafting in patients with moderate ischemic mitral valve regurgitation: a randomized trial. J Thorac Cardiovasc Surg 138:278–285.
Flynn M, Curtin R, Nowicki ER, et al. 2009. Regional wall motion abnormalities and scarring in severe functional ischemic mitral regurgitation: a pilot cardiovascular magnetic resonance imaging study. J Thorac Cardiovasc Surg 137:1063-1070.
Gorman RC, Gorman JH 3rd, Edmunds LH Jr. 2003. Ischemic mitral regurgitation. In: Cohn L.H., Edmunds L.H. Jr., editors. Cardiac surgery in the adult. New York: McGraw-Hill 51-769.
Grigioni F, Enriquez-Sarano M, Zehr KJ, Bailey KR, Tajik AJ. 2001. Ischemic mitral regurgitation. Long-term outcome and prognostic implications with quantitative Doppler assessment. Circulation. 103:1759–1764.
Hickey MS, Smith LR, Muhlbaier LH, Harrell FE Jr, Reves JG, Hinohara T, et al. 1988. Current prognosis of ischemic mitral regurgitation. Circulation. 78:I51-9.
Kang DH, Kim MJ, Kang SJ, et al. 2006. Mitral valve repair versus revascularization alone in the treatment of ischemic mitral regurgitation. Circulation 114:499.
Kim YH, Czer LS, Soukiasian HJ, De Robertis M, Magliato KE, Blanche C, Raissi SS, Mirocha J, Siegel RJ, Kass RM, et al. 2005. Ischemic mitral regurgitation: revascularization alone versus revascularization and mitral valve repair. Ann Thorac Surg 79:1895–1901.
Kumanohoso T, Otsuji Y, Yoshifuku S, Matsukida K, Koriyama C, Kisanuki A, Minagoe S, Levine RA, Tei C. 2003. Mechanism of higher incidence of ischemic mitral regurgitation in patients with inferior myocardial infarction: quantitative analysis of left ventricular and mitral valve geometry in 103 patients with prior myocardial infarction. J Thorac Cardiovasc Surg 125:135-143.
Lam BK, Gillinov AM, Blackstone EH, et al. 2005. Importance of moderate ischemic mitral regurgitation. Ann Thorac Surg 79:462-470.
Lee R, Li S, Rankin JS, et al. 2011. Fifteen-year outcome trends for valve surgery in North America. Ann Thorac Surg. 91:677-684.
Mallidi HR, Pelletier MP, Lamb J, et al. 2004. Late outcomes in patients with uncorrected mild to moderate mitral regurgitation at the time of isolated coronary artery bypass grafting. J Thorac Cardiovasc Surg 127:636-644.
Penicka M, Linkova H, Lang O, et al. 2009. Predictors of improvement of unrepaired moderate ischemic mitral regurgitation in patients undergoing elective isolated coronary artery bypass graft surgery. Circulation 120:1474-1481.
Roshanali F, Mandegar MH, Yousefnia MA, Alaeddini F, Wann S. 2006. Low-dose dobutamine stress echocardiography to predict reversibility of mitral regurgitation with CABG. Echocardiography 23:31-37.
Ryden T, Bech-Hanssen O, Brandrup-Wognsen G, et al. 2001. The importance of grade 2 ischaemic mitral regurgitation in coronary artery bypass grafting. Eur J Cardiothorac Surg 20:276–81.
Tolis GA Jr, Korkolis DP, Kopf GS, et al. 2002. Revascularization alone (without mitral valve repair) suffices in patients with advanced ischaemic cardiomyopathy and mildto- moderate mitral regurgitation. Ann Thorac Surg 74: 1476–80.
Wong DR, Agnihotri AK, Hung JW, et al. 2005. Long-term survival after surgical revascularization for moderate ischemic mitral regurgitation. Ann Thorac Surg 80:570-577.
How to Cite
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).